Literature DB >> 34889436

When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?

Afaf E W G Osman1.   

Abstract

Rapid advances in sequencing technology have led to the identification of somatic mutations that predispose a significant subset of the aging population to myeloid malignancies. Recently recognized myeloid precursor conditions include clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). These conditions can present diagnostic challenges and produce unwarranted anxiety in some instances. While the risk of progression to myeloid malignancies is very low in CHIP, true CCUS confers an exponential increase in risk. Idiopathic cytopenia of unknown significance (IDUS) lacks the predisposing genetic mutations and has a variable course. In this review we define the early myeloid precursor conditions and their risk of progression. We present our diagnostic approach to patients with unexplained cytopenias and discuss the clinical consequences of CHIP and CCUS.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2021        PMID: 34889436      PMCID: PMC8791167          DOI: 10.1182/hematology.2021000272

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  31 in total

1.  Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2016-08-17       Impact factor: 22.113

Review 2.  Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.

Authors:  Lukasz P Gondek; Amy E DeZern
Journal:  Lancet Haematol       Date:  2019-12-03       Impact factor: 18.959

3.  MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.

Authors:  Brian Kwok; Jeff M Hall; John S Witte; Yin Xu; Prashanti Reddy; Keming Lin; Rachel Flamholz; Bashar Dabbas; Aine Yung; Jenan Al-Hafidh; Emily Balmert; Christine Vaupel; Carlos El Hader; Matthew J McGinniss; Shareef A Nahas; Julie Kines; Rafael Bejar
Journal:  Blood       Date:  2015-10-01       Impact factor: 22.113

Review 4.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

Review 5.  How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes.

Authors:  David P Steensma
Journal:  Blood       Date:  2018-09-05       Impact factor: 22.113

6.  The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia.

Authors:  Gang Zheng; Ping Chen; Aparna Pallavajjalla; Lisa Haley; Lukasz Gondek; Amy Dezern; Hua Ling; Federico De Marchi; Ming-Tseh Lin; Christopher Gocke
Journal:  Am J Hematol       Date:  2019-08-07       Impact factor: 13.265

7.  Somatic TP53 variants frequently confound germ-line testing results.

Authors:  Jeffrey N Weitzel; Elizabeth C Chao; Bita Nehoray; Lily R Van Tongeren; Holly LaDuca; Kathleen R Blazer; Thomas Slavin; D A B M D Facmg; Tina Pesaran; Christina Rybak; Ilana Solomon; Mariana Niell-Swiller; Jill S Dolinsky; Danielle Castillo; Aaron Elliott; Chia-Ling Gau; Virginia Speare; Kory Jasperson
Journal:  Genet Med       Date:  2017-11-30       Impact factor: 8.822

8.  Prediction of acute myeloid leukaemia risk in healthy individuals.

Authors:  Sagi Abelson; Grace Collord; Stanley W K Ng; Omer Weissbrod; Netta Mendelson Cohen; Elisabeth Niemeyer; Noam Barda; Philip C Zuzarte; Lawrence Heisler; Yogi Sundaravadanam; Robert Luben; Shabina Hayat; Ting Ting Wang; Zhen Zhao; Iulia Cirlan; Trevor J Pugh; David Soave; Karen Ng; Calli Latimer; Claire Hardy; Keiran Raine; David Jones; Diana Hoult; Abigail Britten; John D McPherson; Mattias Johansson; Faridah Mbabaali; Jenna Eagles; Jessica K Miller; Danielle Pasternack; Lee Timms; Paul Krzyzanowski; Philip Awadalla; Rui Costa; Eran Segal; Scott V Bratman; Philip Beer; Sam Behjati; Inigo Martincorena; Jean C Y Wang; Kristian M Bowles; J Ramón Quirós; Anna Karakatsani; Carlo La Vecchia; Antonia Trichopoulou; Elena Salamanca-Fernández; José M Huerta; Aurelio Barricarte; Ruth C Travis; Rosario Tumino; Giovanna Masala; Heiner Boeing; Salvatore Panico; Rudolf Kaaks; Alwin Krämer; Sabina Sieri; Elio Riboli; Paolo Vineis; Matthieu Foll; James McKay; Silvia Polidoro; Núria Sala; Kay-Tee Khaw; Roel Vermeulen; Peter J Campbell; Elli Papaemmanuil; Mark D Minden; Amos Tanay; Ran D Balicer; Nicholas J Wareham; Moritz Gerstung; John E Dick; Paul Brennan; George S Vassiliou; Liran I Shlush
Journal:  Nature       Date:  2018-07-09       Impact factor: 49.962

9.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Authors:  T Haferlach; Y Nagata; V Grossmann; Y Okuno; U Bacher; G Nagae; S Schnittger; M Sanada; A Kon; T Alpermann; K Yoshida; A Roller; N Nadarajah; Y Shiraishi; Y Shiozawa; K Chiba; H Tanaka; H P Koeffler; H-U Klein; M Dugas; H Aburatani; A Kohlmann; S Miyano; C Haferlach; W Kern; S Ogawa
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

10.  Cancer therapy shapes the fitness landscape of clonal hematopoiesis.

Authors:  Ryan N Ptashkin; Teng Gao; Ahmet Zehir; Elli Papaemmanuil; Kelly L Bolton; Lior Braunstein; Sean M Devlin; Daniel Kelly; Minal Patel; Antonin Berthon; Aijazuddin Syed; Mariko Yabe; Catherine C Coombs; Nicole M Caltabellotta; Mike Walsh; Kenneth Offit; Zsofia Stadler; Diana Mandelker; Jessica Schulman; Akshar Patel; John Philip; Elsa Bernard; Gunes Gundem; Juan E Arango Ossa; Max Levine; Juan S Medina Martinez; Noushin Farnoud; Dominik Glodzik; Sonya Li; Mark E Robson; Choonsik Lee; Paul D P Pharoah; Konrad H Stopsack; Barbara Spitzer; Simon Mantha; James Fagin; Laura Boucai; Christopher J Gibson; Benjamin L Ebert; Andrew L Young; Todd Druley; Koichi Takahashi; Nancy Gillis; Markus Ball; Eric Padron; David M Hyman; Jose Baselga; Larry Norton; Stuart Gardos; Virginia M Klimek; Howard Scher; Dean Bajorin; Eder Paraiso; Ryma Benayed; Maria E Arcila; Marc Ladanyi; David B Solit; Michael F Berger; Martin Tallman; Montserrat Garcia-Closas; Nilanjan Chatterjee; Luis A Diaz; Ross L Levine; Lindsay M Morton
Journal:  Nat Genet       Date:  2020-10-26       Impact factor: 41.307

View more
  1 in total

Review 1.  Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease.

Authors:  Gregor Hoermann
Journal:  Diagnostics (Basel)       Date:  2022-07-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.